Company recognized for innovations in clinically validated cell therapy for corneal endothelial dystrophies
Jonathan Sparks, JD, PhD Joins Aurion Biotech as Chief Legal Officer
Deep Expertise in Intellectual Property to Support Company’s Innovations December 7, 2022 – Seattle, Boston and Tokyo – Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has appointed Dr. Jonathan Sparks as chief legal officer. Dr. Sparks will lead the company’s global legal…
Aurion Biotech Expands Its Leadership Team
Regulatory Affairs and Clinical Operations Vice Presidents Add Key Expertise as Company Prepares to Initiate U.S. Clinical Trials November 30, 2022 – Seattle, Boston and Tokyo – Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has appointed Sherita Hall as vice president, clinical operations…
Aurion Biotech Wins Prestigious Prix Galien Startup Award
Company recognized for innovations in clinically validated cell therapy for corneal endothelial dystrophiesOctober 27, 2022 – Seattle, Boston and Tokyo – Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has won the prestigious Prix Galien Award for Best Startup in Biotech / Pharma….
Advanced Therapies for Ocular Diseases
We are a clinical-stage biotech company. We aim to restore vision to all who need it by developing a platform of innovative, accessible, and effective advanced therapies. Our first candidate is a patented cell therapy treatment for corneal endothelial disease.